Nightingale Health Plc | Press Release | September 29, 2026 at 09:00:00 EEST
Nightingale Health and Professor Skride's Heart Clinic, a private cardiology clinic in Riga, have entered into a service agreement to offer the Nightingale Health Check in Latvia. The clinic offers the test under its own brand, the Future Health Test. The test assesses a person's risk of developing five common chronic diseases over the next 10 years from a single blood sample, and bookings are already open.
Under the agreement, Professor Skride's Heart Clinic offers the test to its clients, and Nightingale Health analyses the blood samples. From a single blood sample, the Nightingale Health Check produces a 10-year risk estimate for five chronic diseases: heart attack, ischemic stroke, type 2 diabetes, chronic kidney disease, and fatty liver disease. The report also includes the person's Metabolic Age and Metabolic Resilience Score, and shows their blood values, including cholesterol, triglycerides, and kidney function. The clinic's doctors make all clinical decisions under existing medical guidelines; the test helps them identify earlier who would benefit most from preventive action. The test is recommended to be repeated after 3 to 12 months to follow how a person's risks change.
Professor Skride's Heart Clinic’s mission is to extend the average life expectancy in Latvia by seven healthy years, and prevention is a central part of its work. According to the OECD and European Observatory Country Health Profile 2025 for Latvia, life expectancy in Latvia was 76.7 years in 2024, five years below the EU average. Cardiovascular diseases cause more than half of all deaths in the country. The Future Health Test adds early risk detection to the clinic's preventive services. It shows a person's disease risks before symptoms appear, so that the person and their doctor have time to act.
"High-quality treatment alone will not give Latvians seven more healthy years; we also need to identify risk in time to act on it. The Future Health Test gives our clients and our doctors a clinically validated picture of their risk of common chronic diseases from a single blood sample. It fits into the preventive services we already offer," says Dins Smits, Co-Founder and Board Member of Professor Skride's Heart Clinic.
"The risk of cardiovascular disease builds up for years before symptoms appear, and a cardiology clinic with prevention at the centre of its mission is the natural place to detect that risk early. With the Future Health Test, people in Latvia can now learn their disease risks from one blood sample while there is still time to act. Latvia is a new market for us, and Professor Skride's Heart Clinic is a strong partner to start with," says Teemu Suna, CEO and Founder of Nightingale Health.
The Future Health Test can be booked at Professor Skride's Heart Clinic in Riga. More information: https://skride.lv/en/service/future-health-test/
About Professor Skride's Heart Clinic
Professor Skride's Heart Clinic (SIA Profesora Skrides Sirds klīnika) is a private cardiology clinic in the centre of Riga, Latvia, opened in May 2024. Founded and led by cardiologist Professor Andris Skride, the clinic brings together specialists from several disciplines, including cardiologists, heart surgeons, endocrinologists, nutritionists, and physiotherapists. It offers specialist consultations, diagnostic examinations, and preventive health packages. The clinic's mission is to extend the average life expectancy in Latvia by seven healthy years. Read more: https://skride.lv/en/
For Professor Skride's Heart Clinic enquiries: info@skride.lv, +371 60007701
For further information, please contact
Teemu Suna, CEO
ir@nightingalehealth.com
About Nightingale Health
Chronic diseases cause around 75% of deaths globally and place a growing burden on healthcare systems. The way to address this is preventive healthcare, but until recently the tools to detect disease risks at population scale have not existed. Nightingale Health has built them. The Nightingale Health Check is a blood-based risk detection test that identifies risks for multiple chronic diseases, including cardiovascular disease, type 2 diabetes, kidney disease, and fatty liver disease, from a single blood sample. It is designed to be applied population-wide, so healthcare systems can identify the people who would benefit most from preventive action before disease develops.
Nightingale Health's technology is validated in over 1,000 peer-reviewed scientific publications and is used in many of the world's leading health studies, including the UK Biobank. In Finland, the Nightingale Health Check is in nationwide healthcare use, and over 250,000 people have already received their results. Nightingale Health operates globally with a parent company in Finland and subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom, and has customers in more than 34 countries across healthcare and medical research. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/
Image Attachments
Nightingale Health